235 related articles for article (PubMed ID: 30087434)
1. Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.
Shakory S; Watts JJ; Hafizi S; Da Silva T; Khan S; Kiang M; Bagby RM; Chavez S; Mizrahi R
Neuropsychopharmacology; 2018 Oct; 43(11):2249-2255. PubMed ID: 30087434
[TBL] [Abstract][Full Text] [Related]
2. Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.
Plitman E; de la Fuente-Sandoval C; Reyes-Madrigal F; Chavez S; Gómez-Cruz G; León-Ortiz P; Graff-Guerrero A
Schizophr Bull; 2016 Mar; 42(2):415-24. PubMed ID: 26320195
[TBL] [Abstract][Full Text] [Related]
3. TSPO expression and brain structure in the psychosis spectrum.
Hafizi S; Guma E; Koppel A; Da Silva T; Kiang M; Houle S; Wilson AA; Rusjan PM; Chakravarty MM; Mizrahi R
Brain Behav Immun; 2018 Nov; 74():79-85. PubMed ID: 29906515
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol modulation of hippocampal glutamate in early psychosis.
O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
[TBL] [Abstract][Full Text] [Related]
5. Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia.
Nenadic I; Maitra R; Basu S; Dietzek M; Schönfeld N; Lorenz C; Gussew A; Amminger GP; McGorry P; Reichenbach JR; Sauer H; Gaser C; Smesny S
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1661-8. PubMed ID: 26088723
[TBL] [Abstract][Full Text] [Related]
6. In vivo brain endocannabinoid metabolism is related to hippocampus glutamate and structure - a multimodal imaging study with PET,
Watts JJ; Guma E; Chavez S; Tyndale RF; Ross RA; Houle S; Wilson AA; Chakravarty M; Rusjan PM; Mizrahi R
Neuropsychopharmacology; 2022 Oct; 47(11):1984-1991. PubMed ID: 35906490
[TBL] [Abstract][Full Text] [Related]
7. Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration.
Egerton A; Griffiths K; Casetta C; Deakin B; Drake R; Howes OD; Kassoumeri L; Khan S; Lankshear S; Lees J; Lewis S; Mikulskaya E; Millgate E; Oloyede E; Pollard R; Rich N; Segev A; Sendt KV; MacCabe JH
Neuropsychopharmacology; 2023 Feb; 48(3):567-575. PubMed ID: 36456813
[TBL] [Abstract][Full Text] [Related]
8. Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [
Hafizi S; Da Silva T; Gerritsen C; Kiang M; Bagby RM; Prce I; Wilson AA; Houle S; Rusjan PM; Mizrahi R
Neuropsychopharmacology; 2017 Dec; 42(13):2474-2481. PubMed ID: 28604733
[TBL] [Abstract][Full Text] [Related]
9. Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study.
Borgan F; Veronese M; Reis Marques T; Lythgoe DJ; Howes O
Eur Arch Psychiatry Clin Neurosci; 2021 Jun; 271(4):677-687. PubMed ID: 32986150
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical effects of oxytocin in people at clinical high risk for psychosis.
Davies C; Rutigliano G; De Micheli A; Stone JM; Ramella-Cravaro V; Provenzani U; Cappucciati M; Scutt E; Paloyelis Y; Oliver D; Murguia S; Zelaya F; Allen P; Shergill S; Morrison P; Williams S; Taylor D; Lythgoe DJ; McGuire P; Fusar-Poli P
Eur Neuropsychopharmacol; 2019 May; 29(5):601-615. PubMed ID: 30928180
[TBL] [Abstract][Full Text] [Related]
11. Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.
Bossong MG; Antoniades M; Azis M; Samson C; Quinn B; Bonoldi I; Modinos G; Perez J; Howes OD; Stone JM; Allen P; McGuire P
JAMA Psychiatry; 2019 Feb; 76(2):199-207. PubMed ID: 30427993
[TBL] [Abstract][Full Text] [Related]
12. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
[TBL] [Abstract][Full Text] [Related]
13. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.
Merritt K; McGuire PK; Egerton A; ; Aleman A; Block W; Bloemen OJN; Borgan F; Bustillo JR; Capizzano AA; Coughlin JM; De la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galinska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes OD; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan M; Kim SY; Kunugi H; Lauriello J; Liemburg EJ; Mcilwain ME; Modinos G; Mouchlianitis ED; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone JM; Szulc A; Taylor R; Thakkar K; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H
JAMA Psychiatry; 2021 Jun; 78(6):667-681. PubMed ID: 33881460
[TBL] [Abstract][Full Text] [Related]
14. Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.
de la Fuente-Sandoval C; Reyes-Madrigal F; Mao X; León-Ortiz P; Rodríguez-Mayoral O; Solís-Vivanco R; Favila R; Graff-Guerrero A; Shungu DC
Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv105. PubMed ID: 26364273
[TBL] [Abstract][Full Text] [Related]
15. Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.
Schifani C; Hafizi S; Tseng HH; Gerritsen C; Kenk M; Wilson AA; Houle S; Rusjan PM; Mizrahi R
Schizophr Res; 2019 Nov; 213():80-86. PubMed ID: 30409695
[TBL] [Abstract][Full Text] [Related]
16. The association between
Beck K; Arumuham A; Brugger S; McCutcheon RA; Veronese M; Santangelo B; McGinnity CJ; Dunn J; Kaar S; Singh N; Pillinger T; Borgan F; Sementa T; Neji R; Jauhar S; Aigbirhio F; Boros I; Turkheimer F; Hammers A; Lythgoe D; Stone J; Howes OD
J Psychopharmacol; 2022 Sep; 36(9):1051-1060. PubMed ID: 36120998
[TBL] [Abstract][Full Text] [Related]
17. Hippocampal glutamate and hippocampus subfield volumes in antipsychotic-naive first episode psychosis subjects and relationships to duration of untreated psychosis.
Briend F; Nelson EA; Maximo O; Armstrong WP; Kraguljac NV; Lahti AC
Transl Psychiatry; 2020 May; 10(1):137. PubMed ID: 32398671
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
Fan L; Liang L; Wang Y; Ma X; Yuan L; Ouyang L; He Y; Li Z; Li C; Chen X; Palaniyappan L
Neuropsychopharmacology; 2024 Apr; 49(5):845-853. PubMed ID: 37752221
[TBL] [Abstract][Full Text] [Related]
19. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.
Stone JM; Howes OD; Egerton A; Kambeitz J; Allen P; Lythgoe DJ; O'Gorman RL; McLean MA; Barker GJ; McGuire P
Biol Psychiatry; 2010 Oct; 68(7):599-602. PubMed ID: 20638047
[TBL] [Abstract][Full Text] [Related]
20. Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [
Hafizi S; Tseng HH; Rao N; Selvanathan T; Kenk M; Bazinet RP; Suridjan I; Wilson AA; Meyer JH; Remington G; Houle S; Rusjan PM; Mizrahi R
Am J Psychiatry; 2017 Feb; 174(2):118-124. PubMed ID: 27609240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
